Skip to main content
. 2019 Apr 3;10:269. doi: 10.3389/fphar.2019.00269

Figure 8.

Figure 8

Ac2-26 reduces cardiac fibrosis at 7 days post I-R injury in vivo. (A) Representative picrosirius red-stained LV cross-sections from sham, vehicle- and Ac2-26-(1mg/kg/day, i.v.)-treated mice, 7-days post I-R (collagen appears red); (B) quantification of cardiac fibrosis. (C) Representative picrosirius red-stained remote area (bright field and polarized light) from sham, vehicle- and Ac2-26-(1mg/kg/day, i.v.)-treated mice, 7-days post I-R, (D) quantification of interstitial fibrosis under polarized light, magnification x200. (E) Representative CardioTAC-stained LV cross-sections from sham, vehicle- and Ac2-26-(1 mg/kg/day, i.v.)-treated mice, 7-days post I-R (magnification x200). (F) Quantification of dead:viable cells (expressed as fold change versus sham; magnification x200. #P < 0.05, ####P < 0.0001 versus sham, ∗P < 0.05 versus vehicle-treated I-R mice. One-way ANOVA with Tukey’s post hoc test. Data were presented as mean ± SEM, with number of mice per group. n = 4 (sham), n = 6 (I-R + vehicle), and n = 6 (I-R + Ac2-26).